P&F Products & Features made a strong showing at New York Valves 2026, the Cardiovascular Research Foundation’s premier structural heart conference, cementing its position at the forefront of transcatheter valve innovation. Across three days of programming, P&F featured prominently in five sessions spanning tricuspid, aortic, and mitral valve technologies โ with the TricValveยฎ Transcatheter Bicaval Valves System taking center stage as a marquee therapy. A clinical case review session allowed attendees to examine real-world TricValve implantations in detail โ walking through patient anatomy, procedural decision-making, imaging guidance, and outcomes. These discussions highlighted both the versatility of the bicaval approach
Lunch Symposium: TricValveยฎ as a Therapy
One of the milestones of P&F’s presence at the conference was the official kickoff of TRICAV II, the pivotal trial evaluating TricValve. This landmark moment signals the program’s transition from promising early-stage data into a rigorous, pivotal evaluation against the standard of care. The trial kickoff generated enthusiasm among the interventional cardiology community and underscored P&F’s commitment to building the clinical evidence base needed to bring this therapy to broader patient populations.
Featured Presentations Across the Scientific Program
Two additional P&F-related presentations took place across morning and afternoon sessions:
- Dr. Diego Gaia presented on AortoSave, P&F’s next-generation transcatheter Bentall platform for integrated endovascular aortic valve and root replacement, featured in the Dedicated TAVR Systems for Aortic Insufficiency innovation session.
- Dr. Marcio Josรฉ Montenegro da Costa introduced The Munich TMVR System during the Innovations in Transcatheter Mitral Valve Replacement session.
Looking Ahead
P&F’s presence at New York Valves 2026 reflected both the breadth of the company’s pipeline and the deepening clinical community around its flagship TricValve system. From regulatory dialogue to the launch of a pivotal trial to peer-reviewed science, the conference marked a pivotal chapter in P&F’s journey toward transforming the treatment of structural heart disease.
CAUTION: The TricValve system is limited by U.S. Federal Law to investigational use. TricValve is MDR-CE-marked and registered with ANVISA.
